TABLE OF CONTENTS
1INTRODUCTION (PAGE NO 36)
1.1Objectives of the Study
1.2Market Definition & Scope
1.2.1Markets covered
Figure 1Cancer/tumor profiling market
1.2.2Years considered for the study
1.3Currency
1.4Stakeholders
1.5Limitations
1.6Summary of Changes
2RESEARCH METHODOLOGY (PAGE NO 40)
2.1Research Approach
Figure 2Research design
2.1.1Secondary research
2.1.1.1Key data from secondary sources
2.1.2Primary research
2.1.2.1Key data from primary sources
2.1.2.2Breakdown of primaries
Figure 3Breakdown of primary interviews: By company type, designation, and region
2.1.2.3Key industry insights
2.2Market Sizing & Validation Approach
Figure 4Segmental share analysis illustration
Figure 5Top-down approach
2.3Data Triangulation Approach
Figure 6Data triangulation methodology
2.4Assumptions for The Study
3EXECUTIVE SUMMARY (PAGE NO 49)
Figure 7Cancer/tumor profiling market, by technology, 2020 vs. 2025 (USD Million)
Figure 8Cancer/tumor profiling market, by cancer type, 2020 vs. 2025 (USD Million)
Figure 9Cancer/tumor profiling market, by biomarker type, 2020 vs. 2025 (USD Million)
Figure 10Cancer/tumor profiling market, by application, 2020 vs. 2025 (USD Million)
Figure 11Geographical snapshot of the cancer/tumor profiling market
4PREMIUM INSIGHTS (PAGE NO 54)
4.1Cancer/Tumor Profiling: Market Overview
Figure 12Increasing demand for personalized medicine to drive market growth
4.2Cancer/Tumor Profiling Market: Geographic Growth Opportunities
Figure 13China to register the fastest growth in the cancer/ tumor profiling market during the forecast period
4.3Regional Mix: Cancer/Tumor Profiling Market (20202025)
Figure 14APAC to witness the fastest growth during the forecast period (20202025)
4.4Cancer/Tumor Profiling Market: Developed Vs. Developing Markets (2020 Vs. 2025)
Figure 15Developing markets to register a higher growth rate between 2020 & 2025
5MARKET OVERVIEW (PAGE NO 58)
5.1Introduction
5.2Market Dynamics
Figure 16Cancer/tumor profiling market: drivers, restraints, opportunities, and challenges
5.2.1Market drivers
5.2.1.1Increasing incidence of cancer
Figure 17Global cancer incidence, 20082030
5.2.1.2Increasing use of biomarkers in cancer profiling
5.2.1.3Increasing cancer research and funding
5.2.1.4Technological advancements
Table 1Market drivers: impact analysis
5.2.2Market restraints
5.2.2.1High capital investment
5.2.2.2Technical issues with sample collection and storage
Table 2Market restraints: impact analysis
5.2.3Market opportunities
5.2.3.1Increasing demand for personalized medicine
Figure 18Launch of personalized medicine products, 20082016
5.2.3.2Growing need for point-of-care diagnostics
Table 3Market opportunities: impact analysis
5.2.4Market challenges
5.2.4.1Low biomarker discovery-to-approval ratio
5.2.4.2Poor regulatory and reimbursement scenario
Table 4Market challenges: impact analysis
6INDUSTRY INSIGHTS (PAGE NO 67)
6.1Introduction
6.2Industry Trends
Figure 19Increasing use of integrated omics data and growing focus on liquid biopsy tests are key market trends
6.2.1Integration of omics data
6.2.2Advances in liquid biopsy
6.2.3Organoids for personalized medicine
6.3COVID-19 Impact on The Cancer/Tumor Profiling Market
Figure 20Impact of COVID-19 on the cancer/tumor profiling market
7CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY (PAGE NO 71)
7.1Introduction
7.2COVID-19 Impact, by Technology
Figure 21Immunoassays to dominate the cancer/tumor profiling market during the forecast period
Table 5Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 6Cancer/tumor profiling market, by technology, 20202025 (USD Million)
7.3Immunoassays
7.3.1Immunoassay tests identify and assess the progression of disease, thereby providing information vital for better therapeutic choices
Table 7Cancer/tumor profiling market for immunoassays, by country/region, 20172019 (USD Million)
Table 8Cancer/tumor profiling market for immunoassays, by country/region, 20202025 (USD Million)
7.4Next Generation Sequencing
7.4.1Advances in ngs multiplexing capabilities enable one assay to provide a complete tumor molecular profile
Table 9Cancer/tumor profiling market for next generation sequencing, by country/region, 20172019 (USD Million)
Table 10Cancer/tumor profiling market for next generation sequencing, by country/region, 20202025 (USD Million)
7.5Polymerase Chain Reaction
7.5.1Real-time pcr helps in the quantification of low-copy transcripts, aiding biomarker identification
Table 11Cancer/tumor profiling market for polymerase chain reaction, by country/region, 20172019 (USD Million)
Table 12Cancer/tumor profiling market for polymerase chain reaction, by country/region, 20202025 (USD Million)
7.6In Situ Hybridization
7.6.1Fish is the gold standard for evaluating some key biomarkers and plays a critical role in guiding targeted therapies
Table 13Cancer/tumor profiling market for in situ hybridization, by country/region, 20172019 (USD Million)
Table 14Cancer/tumor profiling market for in situ hybridization, by country/region, 20202025 (USD Million)
7.7Microarrays
7.7.1Microarrays are widely adopted in diagnostics as they aid in predicting the recurrence of cancer after treatment
Table 15Cancer/tumor profiling market for microarrays, by country/region, 20172019 (USD Million)
Table 16Cancer/tumor profiling market for microarrays, by country/region, 20202025 (USD Million)
7.8Mass Spectrometry
7.8.1Technological advancements are supporting the adoption of this technology for sensitive, reliable, and rapid diagnosis
Table 17Cancer/tumor profiling market for mass spectrometry, by country/region, 20172019 (USD Million)
Table 18Cancer/tumor profiling market for mass spectrometry, by country/region, 20202025 (USD Million)
7.9Other Technologies
Table 19Cancer/tumor profiling market for other technologies, by country/region, 20172019 (USD Million)
Table 20Cancer/tumor profiling market for other technologies, by country/region, 20202025 (USD Million)
8CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE (PAGE NO 90)
8.1Introduction
Figure 22Breast cancer segment to dominate the cancer/tumor profiling market during the forecast period
Table 21Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 22Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
8.2Breast Cancer
8.2.1Breast cancer is the most common cancer found among women
Table 23Cancer/tumor profiling market for breast cancer, by country/region, 20172019 (USD Million)
Table 24Cancer/tumor profiling market for breast cancer, by country/region, 20202025 (USD Million)
8.3Lung Cancer
8.3.1Molecular characterization of tumors using ngs is a key tool for the clinical management of nsclc patients
Figure 23Global lung cancer incidence, 2012-2030
Table 25Cancer/tumor profiling market for lung cancer, by country/region, 20172019 (USD Million)
Table 26Cancer/tumor profiling market for lung cancer, by country/region, 20202025 (USD Million)
8.4Colorectal Cancer
8.4.1IHC, PCR, microarrays, and imaging technologies are major technologies used in colorectal diagnostics
Figure 24Colorectal cancer incidence rate, key countries (2018)
Table 27Cancer/tumor profiling market for colorectal cancer, by country/region, 20172019 (USD Million)
Table 28Cancer/tumor profiling market for colorectal cancer, by country/region, 20202025 (USD Million)
8.5Prostate Cancer
8.5.1Prostate-specific antigen is a widely used fda-approved biomarker for prostate cancer screening
Table 29Cancer/tumor profiling market for prostate cancer, by country/region, 20172019 (USD Million)
Table 30 Cancer/tumor profiling market for prostate cancer, by country/region, 20202025 (USD Million)
8.6Melanoma
8.6.1RT-QPCR is generally utilized to conduct molecular profiling and analyze biomarkers in melanomas
Table 31Cancer/tumor profiling market for melanoma, by country/region, 20172019 (USD Million)
Table 32Cancer/tumor profiling market for melanoma, by country/region, 20202025 (USD Million)
8.7Other Cancers
Table 33Cancer/tumor profiling market for other cancers, by country/region, 20172019 (USD Million)
Table 34Cancer/tumor profiling market for other cancers, by country/region, 20202025 (USD Million)
9CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE (PAGE NO 107)
9.1Introduction
Figure 25Genetic biomarkers to dominate the cancer/tumor profiling market during the forecast period
Table 35Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 36Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
9.2Genetic Biomarkers
9.2.1Genetic biomarkers are frequently used in clinical practice for diagnosis and prognosis
Table 37Cancer/tumor profiling market for genetic biomarkers, by country/region, 20172019 (USD Million)
Table 38cancer/tumor profiling market for genetic biomarkers, by country/region, 2020-2025 (USD Million)
9.3Protein Biomarkers
9.3.1Proteomic methods showcase significant promise for the discovery of novel biomarkers
Table 39Cancer/tumor profiling market for protein biomarkers, by country/region, 20172019 (USD Million)
Table 40Cancer/tumor profiling market for protein biomarkers, by country/region, 20202025 (USD Million)
9.4Other Biomarkers
Table 41Cancer/tumor profiling market for other biomarkers, by country/region, 20172019 (USD Million)
Table 42Cancer/tumor profiling market for other biomarkers, by country/region, 20202025 (USD Million)
10CANCER/TUMOR PROFILING MARKET, BY APPLICATION (PAGE NO 116)
10.1Introduction
10.2COVID-19 Impact, by Application
Figure 26Research applications to dominate the cancer/tumor profiling market during the forecast period
Table 43Cancer/tumor profiling market, by application, 20172019 (USD Million)
Table 44Cancer/tumor profiling market, by application, 20202025 (USD Million)
10.3Research Applications
Table 45Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 46Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
10.3.1Biomarker discovery
10.3.1.1Biomarkers are being exploited for the development of personalized or precision medicine
Table 47Cancer/tumor profiling market for biomarker discovery, by country/region, 20172019 (USD Million)
Table 48Cancer/tumor profiling market for biomarker discovery, by country/region, 20202025 (USD Million)
10.3.2Personalized medicine
10.3.2.1The field of personalized medicine is witnessing rapid growth in the area of oncology
Table 49Cancer/tumor profiling market for personalized medicine, by country/region, 20172019 (USD Million)
Table 50Cancer/tumor profiling market for personalized medicine, by country/region, 20202025 (USD Million)
10.4Clinical Applications
Table 51Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 52Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
10.4.1Diagnostics
10.4.1.1Tumor profiling is rapidly gaining momentum in the area of diagnostics
Table 53Cancer/tumor profiling market for diagnostics, by country/region, 20172019 (USD Million)
Table 54Cancer/tumor profiling market for diagnostics, by country/region, 20202025 (USD Million)
10.4.2Prognostics
10.4.2.1Advancements in molecular biology are aiding the uptake of tumor profiling in this segment
Table 55Cancer/tumor profiling market for prognostics, by country/region, 20172019 (USD Million)
Table 56Cancer/tumor profiling market for prognostics, by country/region, 20202025 (USD Million)
10.4.3Monitoring & treatment
10.4.3.1Multiplatform profiling analyses are gaining recognition for monitoring and treatment among cancer patients
Table 57Cancer/tumor profiling market for monitoring & treatment, by country/region, 20172019 (USD Million)
Table 58Cancer/tumor profiling market for monitoring & treatment, by country/region, 20202025 (USD Million)
10.4.4Screening
10.4.4.1Screening tests help in deciding if diagnostic tests are required by the patient
Table 59Cancer/tumor profiling market for screening, by country/region, 20172019 (USD Million)
Table 60Cancer/tumor profiling market for screening, by country/region, 20202025 (USD Million)
11CANCER/TUMOR PROFILING MARKET, BY REGION
11.1Introduction
11.2COVID-19 Impact, by Region
Figure 27Cancer/tumor profiling market: geographic snapshot
Table 61Cancer/tumor profiling market, by region, 20172019 (USD Million)
Table 62Cancer/tumor profiling market, by region, 20202025 (USD Million)
11.3North America
Figure 28North America: Cancer/tumor profiling market snapshot
Table 63North America: Cancer/tumor profiling market, by country, 20172019 (USD Million)
Table 64North America: Cancer/tumor profiling market, by country, 20202025 (USD Million)
Table 65North America: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 66North America: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 67North America: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 68North America: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 69North America: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 70North America: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 71North America: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 72North America: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 73North America: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 74North America: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.3.1US
11.3.1.1US dominates the North American cancer/tumor profiling market
Table 75US: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 76US: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 77US: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 78US: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 79US: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 80US: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 81US: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 82US: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 83US: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 84US: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.3.2Canada
11.3.2.1Growing public-private partnerships to promote proteomics research are expected to drive the market in Canada
Table 85Canada: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 86Canada: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 87Canada: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 88Canada: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 89Canada: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 90Canada: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 91Canada: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 92Canada: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 93Canada: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 94Canada: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.4Europe
Figure 29Europe: Cancer/tumor profiling market snapshot
Table 95Europe: Cancer/tumor profiling market, by country, 20172019 (USD Million)
Table 96Europe: Cancer/tumor profiling market, by country, 20202025 (USD Million)
Table 97Europe: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 98Europe: Cancer/tumor profiling market, by technology,20202025 (USD Million)
Table 99Europe: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 100Europe: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 101Europe: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 102Europe: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 103Europe: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 104Europe: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 105Europe: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 106Europe: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.4.1Germany
11.4.1.1Advancements in proteomics and genomics research are expected to drive market growth
Table 107Germany: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 108Germany: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 109Germany: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 110Germany: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 111Germany: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 112Germany: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 113Germany: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 114Germany: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 115Germany: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 116Germany: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.4.2UK
11.4.2.1Growth in the life sciences industry and the increase in academia-industry partnerships will be the key factors driving the market
Table 117UK: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 118UK: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 119UK: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 120UK: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 121UK: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 122UK: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 123UK: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 124UK: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 125UK: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 126UK: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.4.3France
11.4.3.1Growth in this market is primarily driven by increasing investments in life science R&D for infrastructural development
Table 127France: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 128France: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 129France: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 130France: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 131France: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 132France: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 133France: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 134France: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 135France: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 136France: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.4.4Italy
11.4.4.1Increasing investment in cancer and translational research is expected to propel market growth during the forecast period
Table 137Italy: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 138Italy: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 139Italy: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 140Italy: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 141Italy: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 142Italy: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 143Italy: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 144Italy: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 145Italy: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 146Italy: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.4.5Spain
11.4.5.1Rising incidence of cancer and increasing focus on cancer biomarkers by various medical societies to support market growth in Spain
Table 147Spain: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 148Spain: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 149Spain: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 150Spain: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 151Spain: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 152Spain: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 153Spain: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 154Spain: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 155Spain: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 156Spain: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.4.6Rest of Europe
Table 157Rest of Europe: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 158Rest of Europe: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 159Rest of Europe: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 160Rest of Europe: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 161Rest of Europe: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 162Rest of Europe: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 163Rest of Europe: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 164Rest of Europe: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 165Rest of Europe: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 166Rest of Europe: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.5Asia Pacific
Figure 30Asia Pacific: Cancer/tumor profiling market snapshot
Table 167Asia Pacific: Cancer/tumor profiling market, by country, 20172019 (USD Million)
Table 168Asia Pacific: Cancer/tumor profiling market, by country, 20202025 (USD Million)
Table 169Asia Pacific: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 170Asia Pacific: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 171Asia Pacific: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 172Asia Pacific: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 173Asia Pacific: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 174Asia Pacific: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 175Asia Pacific: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 176Asia Pacific: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 177Asia Pacific: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 178Asia Pacific: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.5.1Japan
11.5.1.1Large number of research initiatives towards the development of precision medicine supporting market growth in Japan
Table 179Japan: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 180Japan: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 181Japan: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 182Japan: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 183Japan: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 184Japan: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 185Japan: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 186Japan: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 187Japan: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 188Japan: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.5.2China
11.5.2.1China has the fastest-growing research sector in the APAC region
Table 189China: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 190China: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 191China: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 192China: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 193China: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 194China: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 195China: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 196China: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 197China: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 198China: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.5.3India
11.5.3.1Increasing pharma R&D and government funding in the biotechnology industry are the major factors driving market growth in India
Table 199India: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 200India: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 201India: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 202India: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 203India: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 204India: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 205India: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 206India: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 207India: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 208India: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.5.4Rest of Asia Pacific
Table 209Rest of Asia Pacific: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 210Rest of Asia Pacific: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 211Rest of Asia Pacific: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 212Rest of Asia Pacific: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 213Rest of Asia Pacific: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 214Rest of Asia Pacific: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 215Rest of Asia Pacific: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 216Rest of Asia Pacific: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 217Rest of Asia Pacific: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 218Rest of Asia Pacific: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.6Latin America
11.6.1Growing proteomics research in the field of cancer along with the rising use of advanced techniques to drive market growth
Table 219Latin America: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 220Latin America: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 221Latin America: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 222Latin America: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 223Latin America: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 224Latin America: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 225Latin America: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 226Latin America: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 227Latin America: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 228Latin America: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
11.7Middle East & Africa
11.7.1Growing genomics and proteomics research and increasing research collaborations are expected to support market growth
Table 229Middle East: Cancer/tumor profiling market, by technology, 20172019 (USD Million)
Table 230Middle East: Cancer/tumor profiling market, by technology, 20202025 (USD Million)
Table 231Middle East: Cancer/tumor profiling market, by cancer type, 20172019 (USD Million)
Table 232Middle East: Cancer/tumor profiling market, by cancer type, 20202025 (USD Million)
Table 233Middle East: Cancer/tumor profiling market, by biomarker type, 20172019 (USD Million)
Table 234Middle East: Cancer/tumor profiling market, by biomarker type, 20202025 (USD Million)
Table 235Middle East: Cancer/tumor profiling market for research applications, by type, 20172019 (USD Million)
Table 236Middle East: Cancer/tumor profiling market for research applications, by type, 20202025 (USD Million)
Table 237Middle East: Cancer/tumor profiling market for clinical applications, by type, 20172019 (USD Million)
Table 238Middle East: Cancer/tumor profiling market for clinical applications, by type, 20202025 (USD Million)
12COMPETITIVE LANDSCAPE (PAGE NO 224)
12.1Overview
Figure 31Collaborations, partnerships, and agreementskey growth strategy adopted by market players from 2016 to april 2020
12.2Competitive Leadership Mapping
12.2.1Visionary leaders
12.2.2Innovators
12.2.3Dynamic differentiators
12.2.4Emerging companies
Figure 32Cancer/tumor profiling market: competitive leadership mapping (2018)
12.3Competitive Situation And Trends
12.3.1Product launches, approvals, and enhancements
Table 239Product launches, 20162020
12.3.2Expansions
Table 240Expansions, 20162020
12.3.3Acquisitions
Table 241Acquisitions, 20162020
12.3.4Other strategies
Table 242Other strategies, 20162020
13COMPANY PROFILES (PAGE NO 231)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
13.1ILLUMINA, INC.
Figure 33ILLUMINA, INC.: Company snapshot (2019)
13.2QIAGEN N.V.
Figure 34QIAGEN N.V.: Company snapshot (2019)
13.3NEOGENOMICS, INC.
Figure 35NEOGENOMICS, INC.: Company snapshot (2019)
13.4SYSMEX CORPORATION
Figure 36SYSMEX CORPORATION: Company snapshot (2019)
13.5HTG MOLECULAR DIAGNOSTICS, INC.
Figure 37HTG MOLECULAR DIAGNOSTICS, INC.: Company snapshot (2019)
13.6HELOMICS CORPORATION
13.7CARIS LIFE SCIENCES
13.8NANOSTRING TECHNOLOGIES, INC.
Figure 38NANOSTRING TECHNOLOGIES, INC.: Company snapshot (2019)
13.9RIBOMED BIOTECHNOLOGIES, INC.
13.10GUARDANT HEALTH, INC.
Figure 39GUARDANT HEALTH, INC.: Company snapshot (2019)
13.11FOUNDATION MEDICINE
13.12F. HOFFMANN-LA ROCHE LTD
Figure 40F. HOFFMANN-LA ROCHE LTD: Company snapshot (2019)
13.13GENSCRIPT BIOTECH CORPORATION
Figure 41GENSCRIPT: Company snapshot (2019)
13.14TEMPUS LABS
13.15HISTOGENE X
13.16Other Companies
13.16.1HOLOGIC, INC.
13.16.2BOREAL GENOMICS INC
13.16.3PERTHERA
13.16.4AGENDIA
13.16.5OMNISEQ
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
14APPENDIX (PAGE NO 293)
14.1Insights of Industry Experts
14.2Discussion Guide
14.3knowledge Store: Marketsandmarkets Subscription Portal
14.4Available Customizations
14.5Related Reports
14.6Author Details
Growth opportunities and latent adjacency in Cancer/Tumor Profiling Market